Ivabradine Brillpharma

Ivabradine, the active ingredient in Ivabradine Brillpharma, is an If channel inhibitor presented as an oral formulation for oral use. It reduces heart rate and is indicated for chronic stable angina and heart failure with reduced ejection fraction in adult patients.

GNH USA supplies Ivabradine Brillpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution. This includes batch release certificates and stability data to support import requirements.

Ivabradine selectively inhibits the funny (If) current in the sinoatrial node, thereby lowering heart rate without affecting contractility, which is valuable in certain cardiovascular diseases. - Chronic stable angina: reduces the frequency of angina attacks, improves exercise capacity, and may decrease the need for additional anti‑ischemic medications. - Heart failure with reduced ejection fraction: lowers resting heart rate, diminishes myocardial oxygen demand, and contributes to reduced hospitalization rates in eligible patients. - Stable coronary artery disease: assists in symptom control by decreasing heart‑rate‑related oxygen consumption, complementing other anti‑anginal therapies.

Ivabradine may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects: - Visual disturbances (phosphenes): transient luminous phenomena. - Bradycardia: resting heart rate below 50 bpm. - Headache. - Dizziness.

Serious or Rare Side Effects: - Severe symptomatic bradycardia requiring medical intervention. - Atrial fibrillation. - Hypotension.

When prescribing Ivabradine, clinicians should consider several precautionary measures to ensure patient safety. - Baseline heart rate assessment: confirm resting heart rate ≥ 60 bpm before initiation. - Contraindication in severe hypotension: avoid use in patients with systolic BP < 90 mmHg. - Caution in sick sinus syndrome: do not use in patients with known sinus node dysfunction. - Hepatic impairment: dose adjustment may be required in moderate to severe liver disease. - Drug interactions: review concomitant use of strong CYP3A4 inhibitors or other bradycardic agents. - Store at ambient temperature: keep tablets in original packaging, protect from moisture and heat.

Ivabradine interacts with several medicines, some of which require avoidance and others close monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase plasma levels. - Other heart‑rate‑lowering drugs (beta‑blockers, digoxin, diltiazem): risk of excessive bradycardia. - Concomitant use with drugs that prolong AV conduction (e.g., verapamil): may cause conduction disturbances.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may raise concentrations modestly. - Diuretics causing electrolyte imbalance: monitor potassium and magnesium levels. - Antihypertensive agents: adjust blood pressure monitoring as additive effect possible.